Abeona Therapeutics Inc. (ABEO) Sees Strong Trading Volume
Abeona Therapeutics Inc. (NASDAQ:ABEO) saw strong trading volume on Tuesday . 172,700 shares were traded during trading, an increase of 30% from the previous session’s volume of 132,999 shares.The stock last traded at $4.11 and had previously closed at $4.20.
Several research analysts have commented on the stock. Maxim Group set a $6.00 price objective on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 18th. FBR & Co set a $15.00 price objective on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 18th. Zacks Investment Research raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday. Finally, Rodman & Renshaw reissued a “buy” rating and set a $17.00 target price on shares of Abeona Therapeutics in a research note on Sunday, August 21st.
The company’s market capitalization is $140.89 million. The stock’s 50 day moving average price is $3.34 and its 200 day moving average price is $2.85.
Abeona Therapeutics (NASDAQ:ABEO) last announced its earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by $0.06. On average, equities research analysts predict that Abeona Therapeutics Inc. will post ($0.71) EPS for the current fiscal year.
Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.